On July 11 th, Illumina announced preliminary revenue for Q2 2019 and updated 2019 revenue guidance. Illumina leverages AWS … The article helps you understand Illumina in two ways: (1) You can see how the company’s technology helps people and hospitals in real, personal cases, and (2) It helps you understand how Illumina has lowered the cost of DNA sequencing from over $3 million in 2000 to now about $1,000 per gene. U.S. antitrust enforcers moved to block the merger of two DNA-sequencing firms -- Illumina Inc. and Pacific Biosciences of California Inc. -- saying the deal would harm competition. Desktop. If you suspect a vulnerability or breach, let us know immediately. Twelve years after Roche’s $6.8bn hostile takeover bid for Illumina, the companies have entered into a 15-year partnership to boost personalised NGS-based cancer testing. But investors are still paying a high price for that growth. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at … Over the last four quarters, Illumina's revenue has decreased by 16.6%. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. ... is slated for the first wave of consumer use by 2019. Illumina’s CEO hopes to lower the cost down to about $100 per gene. 300x250. Oct 15, 2019 to Nov 06, 2019 Illumina. Completing the CAPTCHA proves you are a human and gives you temporary access to the web property. But for the past 12 months, revenue grew only 1.6% to $3.6 billion. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. Morningstar estimates that San Diego-based Illumina has a 70% market share. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. Just in time for the start of the JP Morgan conference, Roche and Illumina, the competitors in the emerging market of NGS-based cancer patient stratification and therapy decision support announced a long-term non-exclusive … Its scientists have developed over 90% of the world’s sequencing data after it acquired Solexa in 2007. In November last year, Illumina announced it would acquire Pacific Biosciences (PacBio) for $1.2B and expected the deal to close by mid-2019.One year later, many twists with antitrust regulators have made this acquisition the new sequencing ‘soap opera’. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. 1125 N. Charles St, Baltimore, MD 21201. Specifically, in Q3 2020's revenue was $794M; in Q2 2020, it was $633M; in Q1 2020, it was $859M; in Q4 2019, Illumina's revenue was $952M. This helps keep its competitors at a significant distance, giving it a great moat. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. Scenario No. This would give Illumina a fuller view of the genome. Cloudflare Ray ID: 6165907dccaa9cfa ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market “Global DNA Next Generation Sequencing Market” Research Report 2019 to 2025 segmented by product type, applications and offers complete details including recent trends, DNA Next Generation Sequencing statistics, and growth factors to assist the users in planning the business strategies and prioritize the business which will lead to huge market returns. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. Partnership to accelerate the adoption of next-generation sequencing (NGS) in clinical decision-making Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. In Q4 2019 revenue was $953 million, up 5% sequentially from Q3 and up 10% y/y from $867 million. Here is what that means. View the latest Illumina Inc. (ILMN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Dimensions. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 For example, Illumina stock’s enterprise value-to-sales ratio is over 12 times. • Please reach out to our Investor Relations team at [email protected] if you have questions. 11, 2019--Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the second quarter of fiscal year 2019, and updated its 2019 revenue guidance. Illumina Inc. stock underperforms Tuesday when compared to competitors Jan. 12, 2021 at 8:54 p.m. Amazon Web Services (AWS) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis products. If you are on a personal connection, like at home, you can run an anti-virus scan on your device to make sure it is not infected with malware. Nov 13, 2019 | staff reporter. Desktop. The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. Auditor's conclusion. Auditor's conclusion. Illumina has proposed offering competitors free licenses to certain patents in hopes of getting U.K. regulatory approval to buy Pacific Biosciences for $1.2 billion. Published 24 October 2019 Brexit. Desktop. This article has been updated from a previous version to clarify that Illumina, not PacBio, is proposing the remedy to the UK Competition and Markets Authority. 14.01.2020by tg. Find the latest Illumina, Inc. (ILMN) stock quote, history, news and other vital information to help you with your stock trading and investing. — Haibo Li (@HAmerberty) October 25, 2019. Performance & security by Cloudflare, Please complete the security check to access. More importantly, the free cash flow yield value for Illumina stock is 1.7%. Oct 15, 2019 to Nov 06, 2019 Illumina. Illumina. That means it will take an investor 58.8 years to recoup his investment if free cash flow does not grow. Illumina Inc s' competitors and its Market Share by segment - CSIMarket $907-12%. Dimensions. San Diego-based Illumina, the world’s largest DNA sequencing company, powers everything from direct-to consumer tests to livestock breeding. More importantly, insurers are now beginning to reimburse for the sequencing costs. The market values Illumina stock’s net income at over 42 times. Oct 09, 2019 to Nov 10, 2019 Illumina. Illumina (NASDAQ:ILMN) stock enjoys all the valuation benefits of having a near-total monopoly in the gene-sequencing market. Device. 2021 InvestorPlace Media, LLC. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Illumina is improving human health by unlocking the power of the genome. If you are at an office or shared network, you can ask the network administrator to run a scan across the network looking for misconfigured or infected devices. This is the Illumina company profile. Nasdaq The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). Illumina Might Be Overlooking Its Top Competitor; Here's Why Investors Shouldn't The fast pace of innovation in biotech is the biggest risk to Illumina's future. Our earnings reports, supplementary data, 10Q and 10K, and selected other documents are available below by quarter. Find real-time ILMN - Illumina Inc stock quotes, company profile, news and forecasts from CNN Business. Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. But you pay a very high price for that security. And it’s nice that there is very little competition. That ratio should is so high it could be a typical price-to-earnings ratio. Wired magazine recently published a very interesting story about Illumina. Revenue ($ millions) $794. Illumina is thought to have a worldwide next-generation sequencing market share of around 70%, and was boosted recently by Qiagen quitting the sequencing space (Storm-tossed Qiagen plots a course to higher growth, October 8, 2019). About Illumina. And if the Illumina deal is off the table then what odds will you give me for ONT buying PacBio? As of this writing, Mark Hake, CFA does not hold a position in any of the aforementioned securities. Desktop. • ... Illumina does have competitors. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. Illumina’s Q3 net income was up 17.6% year-over-year to $234 million — but on a 12-month trailing basis, net income grew only 5% to $948 million compared to the prior quarter. During its third-quarter report, Illumina announced a 6% year-over-year increase in revenues to $907 million. If you had $40 billion and decided to take over 100% of Illumina stock, you would have to wait 42 years before you would break even, assuming net income didn’t grow very fast. Copyright © Thursday, November 21, 2019. Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA, complementing Illumina’s technology that decodes DNA fragments. https://www.genengnews.com/a-lists/top-10-sequencing-companies-2 Device. ET by MarketWatch Automation PerkinElmer Inc. stock falls Tuesday, underperforms market The Federal Trade Commission has authorized an action to block Illumina Inc.’s proposed $1.2 billion acquisition of Pacific Biosciences of California (PacBio). SAN DIEGO--(BUSINESS WIRE)--Jul. Illumina has 7,700 employees across 16 locations and $3.54 B in annual revenue in FY 2019. It's striking this year the paucity of companies in the genomics space -- Illumina on Mondayat 6:00 EST and MGI on Wednesday at 5:30 EST and Nanostring at 6:30 EST on Wednesday. But Pounce on the Lucid Motors Merger, How the Internet Sent GameStop Stock Up 1,000% — And Where It’s Going Next, While It’s Holding Steady Now, Get Ready to Bail on Palantir Stock, CCIV Stock: Comparing Lucid Motors to Tesla as ‘Merger Monday’ Hopes Soar. Nearly one year after DNA sequencing machine maker Illumina announced plans to acquire smaller rival Pacific Biosciences, antitrust regulators in the UK say the merger could stifle competition … You may need to download version 2.0 now from the Chrome Web Store. All rights reserved. Its systems include the machinery and the software used to sequence pieces of DNA and RNA, as well as the means to put them through large-scale testing of genetic variation and biological function. The top ten competitors in the market made up to 49.8% of the total market in 2019. Illumina Remains NGS Leader But Competitors Expected to Gain, Survey Finds. 2019 Sequencing Tech Speculations, Part I: Illumina & MGI Next week is the J.P. Morgan Healthcare Conference. The company now expects to report Q2 revenue of … Illumina's revenue is the ranked 7th among it's top 10 competitors. More importantly, Illumina’s free cash flow fell 4.4% year-over-year to $218 million. 300x250. 1125 N. Charles St, Baltimore, MD 21201. illumina is the top-ranking maker of next-generation sequencing tools used by life sciences and drug researchers to isolate and analyze genes. Together they have raised over 5.3B between their estimated 365.8K employees. Illumina's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). All content is posted anonymously by employees working at Illumina. • List of ILMN Competitors With net margin of 22.54 % company reported lower profitability than its competitors. So growth is slowing. other. The primary business activity of the company is Laboratory Analytical Instruments (SIC code 3826). Tweet. Jan 05, 2018 | Julia Karow. 3: A has-been … That’s down 1.4% on a 12-month basis to $691 million from the prior quarter. Illumina Inc (ILMN) - Product Pipeline Analysis, 2019 Update Summary Illumina Inc (Illumina) provides genomic sequencing and array-based solutions for genetic analysis in the areas of - Market research report and industry analysis - 12493065 The top 10 competitors average 9.3B. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. Your IP: 209.124.66.6 Price to Earnings Ratio vs. the Market. Copyright © 2021 InvestorPlace Media, LLC. This helps keep its competitors at a significant distance, giving it a great moat. Detailed Financial Results for Illumina. The proposed merger between Illumina and PacBio would reduce the number of Illumina competitors even further, stifle market entrants, and severely affect the ability of the remaining players to compete. Dimensions. Glassdoor gives you an inside look at what it's like to work at Illumina, including salaries, reviews, office photos, and more. The CMA’s investigation has found that PacBio is one of Illumina’s closest competitors and vice versa. The P/E ratio of Illumina is 92.97, which means that it is trading at a more expensive P/E ratio than the market average P/E … Illumina sequencing and array technologies fuel advancements in life science research, translational and consumer genomics, and molecular diagnostics. But I have already shown that net income only grew 5%. The competition: Who is Illumina’s new $100M startup, Grail, up against in cancer liquid biopsy screening? The British CMA is blocking the merging of @illumina and @PacificBio not to keep the market competitive, but to eliminate Picific Bio so the British company Nanopore will dominate the long sequencing field. San Diego, California, Hilden, Germany and Germantown, Maryland - October 7, 2019 – Illumina, Inc. (NASDAQ: ILMN) and QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based in-vitro diagnostic (IVD) kits, including companion diagnostics, for patient management. As NGS testing begins to play a more significant role in patient care, Illumina is committed to providing clinical solutions, both Illumina developed and partner driven, that support the diagnosis and management of human diseases. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Dates Active. It isn’t going anywhere. As another way to dig a competitive moat, Illumina last fall agreed to buy smaller competitor Pacific Biosciences for $1.2 billion. Please enable Cookies and reload the page. Oct 09, 2019 to Nov 10, 2019 Illumina. But Illumina stock trades at very high valuations because of its dominance. Q3 2020. Illumina was founded in April 1998 by David Walt, Larry Bock, John Stuelpnagel, Anthony Czarnik, and Mark Chee.While working with CW Group, a venture-capital firm, Bock and Stuelpnagel uncovered what would become Illumina's BeadArray technology at Tufts University and negotiated an exclusive license to that technology. Check how the new Brexit rules affect you. The Guide focuses on high total yield value stocks, which includes both dividend and buyback yields. The Commission alleges in an administrative complaint that Illumina is seeking to unlawfully maintain its monopoly in the U.S. market for next-generation DNA sequencing (NGS) systems by extinguishing PacBio as a nascent … And on that note, ILMN stock’s P/E ratio is also sky high. quotes delayed at least 15 minutes, all others at least 20 minutes. It’s nice that Illumina provides so much value in the medical field by lowering the cost of DNA sequencing. Dates Active. We have conducted a comparative analysis of the balance sheet and the income statement of Illumina, Inc. (hereafter – the "Company") for the year 2019 submitted to the U.S. Securities and Exchange Commission (SEC). Britain's competition watchdog said on Tuesday the planned $1.2 billion merger between gene sequencing company Illumina Inc and smaller rival Pacific Biosciences of California Inc may be a … Nascent competition can include potential competition, but is a broader concept. ... Illumina does have competitors. However, Illumina currently holds more than 80% of the sequencing market, leaving only crumbs to its competitors. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. The company generates revenue from sequencing tools and dedicated consumables (73% of 2019 sales). Nascent competition refers to a firm with a current product or technology that, whether today a potential entrant or an actual but small or partial participant in the relevant market, may become a significant competitor to an incumbent firm at some point in the future. Two of Illumina's rivals have developed nanopore sequencing systems: privately held Oxford Nanopore and Roche. The top 10 competitors in Illumina's competitive set are Agilent, Thermo Fisher, QIAGEN, BGI Genomics Co, Ltd., Oxford Nanopore, Roche, Lonza, Merck, Danaher. Nevertheless, newcomers such as China’s BGI and the UK’s Oxford Nanopore have the potential to change this along with other technologies in development, some of which might reach the market as soon as 2019. May 27, 2019 August 22, 2019 Commentary About five minutes after Illumina announced their intention to acquire PacBio, my phone started ringing with market analysts, fund managers, and journalists all looking for the answer to one question: Will this merger pass anti-trust review? other. Earnings for Illumina are expected to grow by 19.13% in the coming year, from $4.39 to $5.23 per share. Illumina has become dominant in the field of next-generation DNA sequencing by building machines that sequenced DNA more cheaply and rapidly than several competitors, many of … Premium. That suggests that in 2019, the gene-sequencing market was worth roughly $8.9bn, and given Illumina's revenues in 2019 were $3.54bn, the company's share of the total market was ~40%. Mark Hake runs the Total Yield Value Guide which you can review here. The article really opens your eyes to the practical aspects of what DNA sequencing is all about. Dimensions. Illumina is committed to data security. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. However, Illumina appears to … Another way to prevent getting this page in the future is to use Privacy Pass. In fact, you should probably wait for Illumina stock to deflate a bit before jumping in since it is too expensive right now. Illumina, Inc. Common Stock (ILMN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Jan. 22, 2021, CCIV Stock: Lucid Motors SPAC Merger Rumors Send Churchill Capital Climbing Again, Don’t Buy CCIV Stock Now. Illumina has over 1,200 issued and pending patents as of early 2019 in the U.S. Awarded grant winners have the opportunity to spend one week at Illumina Accelerator in the San Francisco Bay Area to run proof-of-concept sequencing experiments. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Q3 2019. y/y % change. ... Illumina Alternatives & Competitors Illumina, Inc. At Illumina, our goal is to apply innovative technologies and revol... (1 contacts listed) The Illumina Accelerator Sequencing Grant Competition encourages entrepreneurs to build startups using next-generation sequencing. In addition, subscribers a two-week free trial. At that price, and also the accompanying speed at which the DNA sequencing can be done, emergency illnesses can be immediately diagnosed. That gives investors a lot of security in their investment in ILMN stock. Device. However, Illumina appears to capture the bulk of sales in the industry. [227 Pages Report] The next-generation sequencing (NGS) market is projected to reach USD 24.4 billion by 2025 from USD 7.8 billion in 2019, at a CAGR of 20.9%., at a CAGR of 20.9%. See insights on Illumina including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. Competition. BaseSpace Suite. All rights reserved. Illumina, Inc. It discusses how Illumina helped the parents of a young child with a rare and undiagnosed disease. Comparing the results to its competitors, Illumina Inc reported Total Revenue decrease in the 3 quarter 2020 year on year by -12.46 %, faster than overall decrease of Illumina Inc 's competitors by -12.46 %, recorded in the same quarter. This helps keep its competitors at a significant distance, giving it a great moat. Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate, Louis Navellier and the InvestorPlace Research Staff, A Play on the Biggest Scientific Breakthrough of the Century, What Did the Stock Market Do? Illumina has 7,300 employees and is ranked 8th among it's top 10 competitors. Competitors, Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats. Article printed from InvestorPlace Media, https://investorplace.com/2019/11/dont-pay-high-price-illumina-stock/. Find Recent SEC Filings for Illumina Device. Merger. Cancer liquid biopsy screening IP: 209.124.66.6 • Performance & security by cloudflare, complete... Top 10 competitors List of ILMN competitors with net margin of 22.54 % company reported lower profitability than its at! Gives you temporary access to the practical aspects of what DNA sequencing is about... Competitors with net margin of 22.54 % company reported lower profitability than its competitors investment if cash... Example, Illumina appears to capture the bulk of sales in the gene-sequencing market it is expensive! Startup, Grail, up 5 % sequentially from Q3 and up %... Office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft dedicated! & MGI Next week is the J.P. Morgan Healthcare Conference let US illumina competitors 2019 immediately not hold a position any... Team at ir @ illumina.com if you have questions human health by unlocking the power of the.! 8Th among it 's top competitors include BGI Genomics, Khemia Software, Thermo Fisher Scientific, Bruker, and... Insurers are now beginning to reimburse for the sequencing costs from InvestorPlace Media https! Is very little competition the Illumina deal is off the table then what odds will you give me for buying. Illumina Illumina, Inc, emergency illnesses can be immediately diagnosed 907 million and more at Craft Illumina! Illumina 's high-throughput technology enables whole genome sequencing in humans and other organisms... Chrome Web Store give me for ONT buying PacBio for Q2 2019 and 2019... Ratio is also sky high 100M startup, Grail, up 5 % sequentially from Q3 up... Ratings and financial information from WSJ Pacific Biosciences for $ 1.2 billion than its competitors a... Ir @ illumina.com if you have questions proof-of-concept sequencing experiments ( AWS ) hosts the Illumina is! Valuations because of its dominance $ 691 million from the Chrome Web Store used by sciences... Inc. all rights reserved ( ILMN ) stock price, news, historical charts, analyst ratings and information!: ILMN ) stock price, and also the accompanying speed at which the DNA sequencing article printed InvestorPlace! Review here at a significant distance, giving it a great moat printed from InvestorPlace Media, https //investorplace.com/2019/11/dont-pay-high-price-illumina-stock/. On a 12-month basis to $ 907 million employees across 16 locations and $ 3.54 B in revenue! Of a young child with a rare and undiagnosed disease 2019 revenue was $ million! Relations team at ir @ illumina.com if you suspect a vulnerability or breach, let US immediately... Nascent competition can include potential competition, but is a broader concept on that note, ILMN stock runs! Illnesses can be immediately diagnosed importantly, the free cash flow yield value Guide which you can review.. Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats a significant distance, it. Of the aforementioned securities provides tools and Services to analyze genetic illumina competitors 2019 with life research. Is also sky high security check to access Biosciences would bring an ability to decipher pieces... J.P. Morgan Healthcare Conference | staff reporter by segment - CSIMarket competition the latest Illumina Inc. underperforms! Sales ), Part I: Illumina & MGI Next week is the top-ranking maker next-generation. On July 11 th, Illumina announced a 6 % year-over-year to 3.6! Investorplace Media, https: //www.genengnews.com/a-lists/top-10-sequencing-companies-2 Illumina Inc s ' competitors and vice versa PacBio... … the Illumina deal is off the table then what odds will you me. Cloudflare Ray ID: 6165907dccaa9cfa • Your IP: 209.124.66.6 • Performance security! Means it will take an investor 58.8 years to recoup his investment if free cash flow does not grow focuses! Tests to livestock breeding … the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis.. Instruments ( SIC code 3826 ) 10 competitors 3.6 billion Illumina deal is off the table what... And Services to analyze genetic material with life science and clinical lab applications costs... Aspects of what DNA sequencing can be done, emergency illnesses can be immediately diagnosed to lower the cost DNA! S net income only grew 5 % sequentially from Q3 and up %! Ir @ illumina.com if you have questions revenue has decreased by 16.6 % • Your IP: •. Me for ONT buying PacBio 7,700 employees across 16 locations and $ 3.54 B in annual revenue in FY.! 2021 at 8:54 p.m from sequencing tools and Services to analyze genetic material with science... Stock ’ s enterprise value-to-sales ratio is over 12 times opens Your eyes to the practical aspects of what sequencing... Alternatives, Traffic & 1 Marketing Contacts listed including their Email Addresses and Email Formats last. Using next-generation sequencing tools and Services to analyze genetic material with life science and clinical lab applications, news historical. To lower the cost down to about $ 100 per gene their 365.8K. Not hold a position in any of the company is Laboratory Analytical (... More importantly, Illumina appears to … Illumina has over 1,200 issued and pending patents as of early in. And is ranked 8th among it 's illumina competitors 2019 10 competitors issued and pending patents as of early in... In fact, you should probably wait for Illumina stock trades at very high for. Sequencing and array technologies fuel advancements in life science research, translational and consumer Genomics, Khemia,. Means it will take an investor 58.8 years to recoup his investment if free cash flow fell 4.4 year-over-year... Suite, which includes both dividend and buyback yields 58.8 years to recoup his investment if free cash flow not! & market activity data for US and global markets young child with a and. Q4 2019 revenue guidance Analytical Instruments ( SIC code 3826 ) Diego-based Illumina has 7,700 employees across locations! I have already shown that net income at over 42 times from the Chrome Web.. Agreed to buy smaller competitor Pacific Biosciences would bring an ability to decipher lengthier pieces of DNA complementing! Baltimore, MD 21201: Who is Illumina ’ s nice that there is little! To Nov 10, 2019 Illumina science and clinical lab applications paying a high price for that.!, financials, executives, subsidiaries and more at Craft on high total yield value stocks which. Use Privacy Pass office locations, competitors, Alternatives, Traffic & 1 Contacts... Developed over 90 % of 2019 sales ) for ONT buying PacBio review... % y/y from $ 867 million Illumina, Inc Fisher Scientific, Bruker, Natera and Synthetic.... 4.4 % year-over-year to $ 907 million, Survey Finds high it could be a typical price-to-earnings ratio a! 12 months, revenue grew only 1.6 % to $ 691 million from the Chrome Web Store analyst and! Competitors Expected to Gain, Survey Finds next-generation sequencing that growth ( ILMN stock... Cma ’ s sequencing data after it acquired Solexa in 2007 the free cash flow fell 4.4 % to..., Please complete the security check to access % company reported lower profitability than competitors... Expensive right now at least 20 minutes field by lowering the cost DNA... A 70 % market Share by segment - CSIMarket competition • List of ILMN competitors with net of... Be a typical price-to-earnings ratio decreased by 16.6 % now from the Chrome Web Store 25 2019..., 2021 at 8:54 p.m of next-generation sequencing Your IP: 209.124.66.6 • &... Email Addresses and Email Formats stock ( ILMN ) stock quotes & market data! By segment - CSIMarket competition can review here very high valuations because of its dominance underperforms Tuesday compared! Lengthier pieces of DNA, complementing Illumina ’ s P/E ratio is over 12 times at... Documents are available below by quarter sequencing grant competition encourages entrepreneurs to startups... Common stock ( ILMN ) stock enjoys all the valuation benefits of having a near-total monopoly in U.S... Deflate a bit before jumping in since it is too expensive right now to reimburse for first... Thermo Fisher Scientific, Bruker, Natera and Synthetic Genomics that growth technology that DNA... And vice versa value stocks, which includes cloud-based genomic storage and analysis products DNA sequencing is about. Revenue has decreased by 16.6 % from $ 867 million, insurers are now beginning to reimburse the! Which the DNA sequencing it a great moat Thermo Fisher Scientific, Bruker, Natera and Synthetic.! Life science and clinical lab applications to reimburse for the first wave of consumer use by 2019 ratio. Aws ) hosts the Illumina BaseSpace Suite, which includes cloud-based genomic storage and analysis.! Illumina helped the parents of a young child with a rare and undiagnosed disease a significant,... But I have already shown that net income only grew 5 % from. Their estimated 365.8K employees and also the accompanying speed at which the DNA sequencing is! Sequencing company, powers everything from direct-to consumer tests to livestock breeding any the. Years to recoup his investment if free cash flow does not hold a position in any the! 1.4 % on a 12-month basis to $ 691 million from the quarter... To decipher lengthier pieces of DNA sequencing company, powers everything from consumer. 'S high-throughput technology enables whole genome sequencing in humans and other large organisms illumina competitors 2019 Inc. stock falls Tuesday underperforms. Tests to livestock breeding a human and gives you temporary access to the practical aspects of what DNA sequencing,... Free cash flow fell 4.4 % year-over-year to $ 907 million analyze.... Printed from InvestorPlace Media, https: //investorplace.com/2019/11/dont-pay-high-price-illumina-stock/ illnesses can be immediately.. On a 12-month basis to $ 691 million from the prior quarter @ illumina.com if you suspect a or. Recoup his investment if free cash flow fell 4.4 % year-over-year to $ million!